DESTINY-Lung04 Shows PFS Benefit With Survival Unresolved
First-line trastuzumab deruxtecan extended blinded-review median progression-free survival to 14.3 from 8.3 months versus pembrolizumab plus platinum-pemetrexed in the randomized Phase III DESTINY-Lung04 trial. Response rate was 70.0% versus 44.5%. The result establishes a…
